Mesoblast Limited (NASDAQ:MESO - Get Free Report) shares passed below its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $13.90 and traded as low as $10.38. Mesoblast shares last traded at $10.51, with a volume of 174,166 shares.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald upgraded Mesoblast to a "strong-buy" rating in a research note on Monday, March 31st. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, Mesoblast presently has a consensus rating of "Moderate Buy" and a consensus price target of $18.00.
Read Our Latest Stock Report on Mesoblast
Mesoblast Trading Up 0.6%
The company has a debt-to-equity ratio of 0.22, a current ratio of 0.96 and a quick ratio of 0.63. The firm has a fifty day simple moving average of $11.24 and a 200 day simple moving average of $13.90.
Institutional Trading of Mesoblast
Institutional investors have recently bought and sold shares of the business. Barclays PLC acquired a new stake in Mesoblast in the fourth quarter valued at approximately $38,000. JPMorgan Chase & Co. acquired a new stake in Mesoblast in the fourth quarter valued at approximately $50,000. BNP Paribas Financial Markets grew its holdings in Mesoblast by 86,566.7% in the fourth quarter. BNP Paribas Financial Markets now owns 2,600 shares of the company's stock valued at $51,000 after purchasing an additional 2,597 shares during the period. Tower Research Capital LLC TRC acquired a new stake in Mesoblast in the fourth quarter valued at approximately $88,000. Finally, Advisors Preferred LLC raised its holdings in shares of Mesoblast by 224.9% during the first quarter. Advisors Preferred LLC now owns 4,578 shares of the company's stock valued at $54,000 after acquiring an additional 3,169 shares during the last quarter. 1.43% of the stock is owned by institutional investors and hedge funds.
About Mesoblast
(
Get Free Report)
Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Mesoblast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Mesoblast wasn't on the list.
While Mesoblast currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
